References
- Allen T. M., Sapra P., Moase E. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mol. Biol. Lett 2002; 7(3)889–894, [INFOTRIEVE], [CSA]
- Antony A. C. Folate receptors: reflections on a personal odyssey and a perspective on unfolding truth. Adv. Drug Deliv. Rev 2004; 56(8)1059–1066, [INFOTRIEVE], [CSA], [CROSSREF]
- Colbern G. T., Hiller A. J., Musterer R. S., et al. Significant increase in antitumor potency of doxorubicin HCI by its encapsulation in pegylated liposomes. J. Liposome Res 1999; 9: 523–538, [CSA]
- Constantinides P. P., Tustian A., Kessler D. R. Tocol emulsions for drug solubilization and parenteral delivery. Adv. Drug Deliv. Rev 2004; 56(9)1243–1255, [INFOTRIEVE], [CSA], [CROSSREF]
- Elnakat H., Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv. Drug Deliv. Rev 2004; 56(8)1067–1084, [INFOTRIEVE], [CSA], [CROSSREF]
- Gabizon A. A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001; 19(4)424–436, [INFOTRIEVE], [CSA], [CROSSREF]
- Gabizon A., Goren D., Horowitz A. T., Tzemach D., Lossos A., Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv. Drug Deliv. Rev 1997; 24: 337–344, [CSA], [CROSSREF]
- Gabizon A., Horowitz A. T., Goren D., Tzemach D., Shmeeda H., Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res 2003; 9(17)6551–6559, [INFOTRIEVE], [CSA]
- Gabizon A., Shmeeda H., Horowitz A. T., Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev 2004; 56(8)1177–1192, [INFOTRIEVE], [CSA], [CROSSREF]
- Gabizon A. A., Tzemach D., Horowitz A. T., Shmeeda H., Yeh J., Zalipsky S. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Clin. Cancer Res 2006; 12(6)1913–1920, [INFOTRIEVE], [CSA], [CROSSREF]
- Gabizon A., Tzemach D., Mak L., Bronstein M., Horowitz A. T. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J. Drug Target 2002; 10(7)539–548, [INFOTRIEVE], [CSA], [CROSSREF]
- Goren D., Horowitz A. T., Tzemach D., Tarshish M., Zalipsky S., Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res 2000; 6(5)1949–1957, [INFOTRIEVE], [CSA]
- Goren D., Horowitz A. T., Zalipsky S., Woodle M. C., Yarden Y., Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br. J. Cancer 1996; 74(11)1749–1756, [INFOTRIEVE], [CSA]
- Harding J. A., Engbers C. M., Newman M. S., Goldstein N. I., Zalipsky S. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim. Biophys. Acta 1997; 1327(2)181–192, [INFOTRIEVE], [CSA], [CROSSREF]
- Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul 2001; 41: 189–207, [INFOTRIEVE], [CSA], [CROSSREF]
- Park J. W., Hong K., Kirpotin D. B., Colbern G., Shalaby R., Baselga J., et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res 2002; 8(4)1172–1181, [INFOTRIEVE], [CSA]
- Parker N., Turk M. J., Westrick E., Lewis J. D., Low P. S., Leamon C. P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem 2005; 338(2)284–293, [INFOTRIEVE], [CSA], [CROSSREF]
- Sapra P., Tyagi P., Allen T. M. Ligand-targeted liposomes for cancer treatment. Curr. Drug Deliv 2005; 2(4)369–381, [INFOTRIEVE], [CSA], [CROSSREF]
- Shmeeda H., Mak L., Tzemach D., Astrahan P., Tarshish M., Gabizon A. Intra-cellular uptake and intra-cavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with upregulated folate receptors. Molecular Cancer Therapeutics 2006, in press[CSA]
- Yuan F., Dellian M., Fukumura D., Leunig M., Berk D. A., Torchilin V. P., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55(17)3752–3756, [INFOTRIEVE], [CSA]
- Yuan F., Leunig M., Huang S. K., Berk D. A., Papahadjopoulos D., Jain R. K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994; 54(13)3352–3356, [INFOTRIEVE], [CSA]
- Zalipsky S., Mullah N., Harding J. A., Gittelman J., Guo L., DeFrees S. A. Poly(ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains. Bioconjug. Chem 1997; 8(2)111–118, [INFOTRIEVE], [CSA], [CROSSREF]
- Zalipsky S., Mullah N., Qazen M. Preparation of poly(ethylene glycol)-grafted liposomes with ligands at the extremities of polymer chains. Methods Enzymol 2004; 387: 50–69, [INFOTRIEVE], [CSA]